hikma.

Press Release

Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA

London, 9 April 2025 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has announced an exclusive licensing agreement with pharmaand GmbH (pharma&), a global pharmaceutical company based in Vienna, Austria.

This agreement grants Hikma exclusive rights to commercialise **rucaparib** across the Middle East and North Africa (MENA) region. Rucaparib, marketed as Rubraca®, is an innovative small-molecule oral therapy designed to inhibit poly (ADP-ribose) polymerases (PARPs), a family of proteins critical to DNA repair in cancer cells. This mechanism makes rucaparib an important treatment option for patients battling ovarian cancer, the 8th most common cancer in women globally[1], and prostate cancer, the 4th most common cancer worldwide and the second most common cancer in men[2].

Rucaparib has received regulatory approval from both the European Medicines Agency (EMA) and the United States Food and Drug Administration (U.S. FDA).

Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA, said: "We are pleased to add rucaparib, an innovative oncology treatment, to our growing oncology portfolio in MENA. This agreement is a major step to further enhance patients' access to life-changing treatments and address critical medical needs across the region. By strengthening our oncology portfolio, we reaffirm our commitment to providing advanced cancer treatments and supporting our purpose of putting better health within reach, every day."

As the company's first innovative small-molecule oral therapy in oncology approved by both the U.S. FDA and EMA, this partnership strengthens Hikma's promise of providing better access to life saving treatment options and its commitment to improving patient outcomes.

– ENDS –

For inquiries:

Mona Abdallah
Sr. Director, MENA Communications
MBAbdallah@Hikma.com / +962 6 5802900

Dana Alhusseini
Associate Director, MENA Communications
DAlhusseini@Hikma.com / +962 6 5802900

Zaina AlAtiyat
Manager, MENA Communications & Corporate Affairs
ZAlAtiyat@hikma.com / +962 6 5802900

[1] Ovarian cancer statistics | World Cancer Research Fund

[2] Prostate cancer statistics | World Cancer Research Fund

About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

About pharma&

pharmaand GmbH (pharma&), a privately owned global company based in Vienna, Austria, aspires to breathe new life into proven medicines. The company is dedicated to preserving the availability and fostering the further development of essential medicines worldwide to leave no patient behind. Over the past five years, pharma& has acquired and integrated 10+ medicines, expanding its portfolio across a wide range of therapy areas, with an increasing focus on hematology and oncology treatments. The company's unique synthesis of subsidiaries, joint ventures, and partners enables pharma& to provide its portfolio of medicines to eligible patients worldwide by spanning the continuum of development, product and API manufacturing, partner distribution, healthcare provider engagement, distribution and services to patients.

pharma& holds the worldwide rights for Rubraca® (rucaparib).

About Rubraca®
Rubraca® (rucaparib) is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2 and PARP3.[3]

Rucaparib is indicated by the European Medicines Agency (EMA) as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.[3]

Rucaparib is also indicated by EMA as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.[3]

Additionally, rucaparib is indicated by U.S. Food and Drug Administration for the treatment of adult patients with a deleterious *BRCA* mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.[4]

3- Electronic medicines compendium (emc), Rubraca, Healthcare Professionals (SmPC). Available at: [https://www.medicines.org.uk/emc/product/14967/smpc].
4- U.S. Food and Drug Administration. Available at: [https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s011lbl.pdf].